Conversely, budesonide reduced the expression of the mesenchymal markers VIMENTIN and FIBRONECTIN (FN1) both in PDAC and PANC1 cells (Fig. 1E-F, and Fig. S1I), providing molecular support to the hypothesis that budesonide induces epithelial features in pancreatic cancer cells. Here, VIM is linked to familial pancreatic carcinoma.